,
5 min read
Software is now a frontline component of care delivery, and that reality is reshaping how companies think about global market access for SaMD. Unlike traditional devices, SaMDs can scale quickly across borders, but it also inherits Regulatory complexity that grows with every new jurisdiction, clinical claim, data dependency, and update cycle.
The core challenge is that “global” does not mean uniform. Even when regulators share common principles, local interpretations differ in how they classify risk, what evidence they prioritize, and how they expect manufacturers to manage change over time. A strong SaMD global market expansion plan therefore begins with a disciplined strategy that can translate across regions without fragmenting into multiple conflicting playbooks.
At its best, SaMD global opportunities come from building a repeatable market-access model, one that treats compliance as a lifecycle system rather than a one-time submission event, and that aligns product decisions with the realities of multi-market oversight.
Why global market access for SaMD is uniquely complex
SaMD expands faster than many Regulatory systems were originally designed to handle. Software releases are frequent, cybersecurity is continuously evolving, and algorithmic performance can shift with data drift or user behaviour. This makes SaMD regulation process maturity, particularly in change control and post-market monitoring, a critical differentiator when scaling from a single market to multiple geographies.
At the same time, global expansion introduces a practical constraint i.e. evidence and documentation must be coherent enough to be reused, but adaptable enough to meet local requirements. That tension is where many teams get stuck. When a Regulatory strategy is developed “per country” without a unifying core, inconsistency creeps into intended use statements, claims language, risk files, and validation narratives, creating delays and rework.
Start with a global core, then layer regional requirements
A scalable SaMD global Regulatory strategy typically follows a “global core + regional overlays” model. The global core defines the device’s intended use, benefit-risk rationale, evidence strategy, and lifecycle governance approach. Regional overlays then address local classification rules, submission formats, labeling conventions, and post-market obligations.
This approach is especially effective when the core is built on widely recognized guidance and terminology. For example, anchoring classification and clinical evaluation logic to IMDRF concepts can make cross-market reasoning more consistent, even when local rules differ. The IMDRF’s SaMD publications provide a helpful reference point for aligning global thinking with regulator expectations in a way that remains portable across regions.
Risk classification drives everything treat it as a strategy decision
Global expansion is often derailed by early misalignment on SaMD risk classification. Classification is not just a label it directly influences the depth of clinical evidence, the rigor of software lifecycle controls, the scope of cybersecurity expectations, and the post-market obligations you inherit. It also shapes how much flexibility you will have for updates once the product is in use.
In practice, teams that do well globally develop a defensible classification rationale that explains two things clearly, the seriousness of the clinical context, and how strongly the software influences clinical decisions. When classification logic is traceable and consistently applied, it becomes easier to map global SaMD Regulatory requirements without rewriting the product story for each jurisdiction.
Evidence portability is the real lever for speed
For multi-market access, the goal is not “more evidence,” but the right evidence structure. Evidence becomes portable when it is modular analytical validation, clinical validation, and usability/human factors are connected into a single narrative that still allows for regional additions.
A common best practice is to define a global evidence plan with clear traceability, then localize only what truly must be localized (such as population considerations, clinical workflow differences, or region-specific Regulatory expectations). In the US, manufacturers often align this approach with the FDA’s SaMD framing. In Europe, the interpretation of software under MDR is frequently informed by MDCG guidance.
The biggest operational risk in global expansion is uncontrolled change
What looks like “speed” in software can look like “instability” to regulators if change control is not disciplined. A credible global SaMD Regulatory strategy anticipates that updates will happen and defines how their impact will be assessed across regions.
This is where organizations need to think beyond submission readiness and invest in lifecycle governance: consistent thresholds for what constitutes a significant change, rules for revalidation, and monitoring that connects real-world performance back to risk controls. Without this, global scaling increases exposure because a single change can trigger obligations in multiple jurisdictions at once.
Strategic considerations: sequencing, resourcing, and governance
Successful SaMD expansion strategy is rarely “enter all markets at once.” It is usually a sequencing decision based on evidence reuse, pathway predictability, and operational capacity to sustain compliance after launch. Many teams start with one or two anchor markets, build a stable post-market and change-control model, then extend into additional geographies using the same global core.
A pragmatic governance model also matters. Global expansion works best when Regulatory, clinical, quality, and engineering teams share a single source of truth for intended use, classification rationale, and validation scope. That alignment reduces drift as the product scales.
Closing perspective
Global access for SaMDs is ultimately about designing for consistency. Consistent claims, consistent evidence logic, and consistent control over change. When those elements are in place, SaMD regulatory strategy becomes a growth architecture not just a compliance exercise and SaMD global Regulatory strategy becomes the mechanism by which innovation can scale responsibly.
In practice, teams that treat global access as a lifecycle discipline linking evidence durability, global SaMD regulatory requirements, and change governance tend to align more consistently with the expectations outlined in the Comprehensive Guide to Software as a Medical Device (SaMD) Compliance & Global Registration.
Contact Freyr Solutions to discuss your SaMD Regulatory strategy and discover how Freyr can streamline your global registrations.
